Bayer AG is investing €100m ($113m) in its Consumer Health division to “enable sustainable innovation, production and consumption” of major OTC brands like Aspirin, Bepanthen, Claritin and Elevit.
Equating to 2% of the division’s sales, Bayer said the investment will help “drive the sustainable use of the company’s products and help create
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?